Results · Apr-Jun 2026 · filed 14 Aug 2026
Gufic BioSciences Q1 FY27 results
Very strongVery strong: sales up 15% or more & profit up 25% or more on the same quarter last year, with a wider operating margin.
Sales grew 17% to ₹261 crore from ₹224 crore in Apr-Jun 2025.
Operating profit grew 40% to ₹46.6 crore, an operating margin of 17.9% (up 3.0 points from a year ago).
Net profit grew 71% to ₹22.3 crore from ₹13.1 crore in Apr-Jun 2025.
Against Jan-Mar 2026: sales +4%, net profit +2%.
Apr-Jun 2026 vs a year ago
| ₹ crore | Apr-Jun 2026 | Apr-Jun 2025 | Change |
|---|---|---|---|
| Sales | 260.8 | 223.7 | +17% |
| Operating profit (EBITDA) | 46.6 | 33.3 | +40% |
| Operating margin | 17.9% | 14.9% | +3.0 pts |
| Net profit | 22.3 | 13.1 | +71% |
Consolidated figures. Margins & ratios change in percentage points (pts).
The earnings call
Apr–Jun 2026 revenue grew to ₹261 crore from ₹227 crore from a year earlier; EBITDA margin expanded to 18.09% from 14.6%. Management expects 15-20% growth from a year earlier & is scaling Indore capacity to 40-45% by year-end while expanding international operations via own field teams in emerging markets.
The last 7 quarters
Filings that week
- 18 Aug 2026Announcement under Regulation 30 (LODR)-Newspaper Publication
- 17 Aug 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
- 15 Aug 2026Announcement under Regulation 30 (LODR)-Newspaper Publication
- 14 Aug 2026Announcement under Regulation 30 (LODR)-Investor Presentation
- 14 Aug 2026Announcement under Regulation 30 (LODR)-Acquisition
- 14 Aug 2026Results - Unaudited Financial Results (Standalone And Consolidated) For The Quarter Ended June 30, 2026
- 14 Aug 2026Board Meeting Outcome for Meeting Held On Friday, August 14, 2026
- 13 Aug 2026Announcement under Regulation 30 (LODR)-Newspaper Publication
From the company's results filed on BSE (Consolidated). Business numbers only. Education & analysis, not investment advice or a recommendation.